Off-the-shelf cancer vaccine shows promise; ‘skin in a syringe’; Apple joins the GLP-1 weight loss wave – Morning Medical Update

Morning Medical Update © meeboonstudio - stock.adobe.com

Off-the-shelf cancer vaccine shows promise in pancreatic, colorectal cancer

An investigational cancer vaccine has triggered strong T-cell immune responses and reduced relapse risk in patients with pancreatic and colorectal cancer, according to final Phase 1 results published in Nature Medicine. The off-the-shelf vaccine, ELI-002 2P, targets KRAS mutations and showed especially durable benefit among patients with high immune responses — many of whom remained disease-free at nearly 20 months of follow-up.

‘Skin in a syringe’ could offer new hope for burn treatment

Researchers at Linköping University have developed a gel-like material containing live cells that can be 3D-printed into a skin graft, potentially offering a breakthrough in treating severe burns. The gel mimics key features of real skin and forms blood vessels when tested in mice. Researchers hope it could help regenerate functional skin without major scarring.

Apple joins GLP-1 weight loss boom with FuturHealth partnership

Apple is bundling its Fitness+ subscription with FuturHealth’s GLP-1 weight-loss therapy program, marking its first integration with a prescription drug service. The move taps into surging demand for GLP-1s like Wegovy and Zepbound and underscores the need for long-term lifestyle support to sustain weight loss. Fitness+ access, now included with FuturHealth plans, aims to deliver that support through workouts, meditations and guided routines. pharmaphorum has more.